-
1.FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS 有权
标题翻译: 熔化双相PYRIMIDINE化合物作为AURORA激酶抑制剂公开(公告)号:US20090275533A1
公开(公告)日:2009-11-05
申请号:US12428044
申请日:2009-04-22
IPC分类号: A61K31/695 , C07D239/70 , C12N9/99 , A61K31/519 , C07D413/14 , A61K31/5377 , A61K31/496 , C07F7/08 , C07D487/02 , A61P35/00
CPC分类号: C07F7/0812 , C07D239/70 , C07D413/14 , C07D487/02
摘要: Fused bicyclic pyrimidine compounds of formula (I): wherein R1, R3, R4, X1, X2, Y, Z, A, B, C, D, n, and the two bonds are defined herein. Also disclosed are a method for inhibiting Aurora kinase activity and a method for treating cancer with these compounds.
摘要翻译: 式(I)的稠合双环嘧啶化合物:其中R1,R3,R4,X1,X2,Y,Z,A,B,C,D,n和两个 还公开了抑制极光激酶活性的方法和用这些化合物治疗癌症的方法。
-
公开(公告)号:US08138194B2
公开(公告)日:2012-03-20
申请号:US12428044
申请日:2009-04-22
IPC分类号: A01N43/90 , A61K31/519 , A01N43/54 , A61K31/505 , C07D487/00 , C07D491/00
CPC分类号: C07F7/0812 , C07D239/70 , C07D413/14 , C07D487/02
摘要: Fused bicyclic pyrimidine compounds of formula (I): wherein R1, R3, R4, X1, X2, Y, Z, A, B, C, D, n, and the two bonds are defined herein. Also disclosed are a method for inhibiting Aurora kinase activity and a method for treating cancer with these compounds.
摘要翻译: 式(I)的稠合双环嘧啶化合物:其中R1,R3,R4,X1,X2,Y,Z,A,B,C,D,n和这两个键在本文中定义。 还公开了抑制极光激酶活性的方法和用这些化合物治疗癌症的方法。
-
3.Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors 有权
标题翻译: 融合的双环和三环嘧啶化合物作为酪氨酸激酶抑制剂公开(公告)号:US08507502B2
公开(公告)日:2013-08-13
申请号:US12614584
申请日:2009-11-09
申请人: Hsing-Pang Hsieh , Selvaraj Mohane Coumar , Tsu-An Hsu , Wen-Hsing Lin , Yi-Rong Chen , Yu-Sheng Chao
发明人: Hsing-Pang Hsieh , Selvaraj Mohane Coumar , Tsu-An Hsu , Wen-Hsing Lin , Yi-Rong Chen , Yu-Sheng Chao
IPC分类号: C07D487/04 , A61K31/519 , A61P35/00
CPC分类号: C07D491/02 , C07D491/04 , C07D495/02 , C07D495/04 , C07D495/12
摘要: Fused bicyclic or tricyclic compounds of formula (I): wherein A, B, C, X, Y, m, and n are defined herein. Also disclosed are a method for inhibiting EGFR kinase activity and a method for treating cancer with these compounds.
摘要翻译: 式(I)的稠合双环或三环化合物:其中A,B,C,X,Y,m和n如本文所定义。 还公开了抑制EGFR激酶活性的方法和用这些化合物治疗癌症的方法。
-
4.Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors 有权
标题翻译: 融合的双环和三环嘧啶化合物作为酪氨酸激酶抑制剂公开(公告)号:US20100120805A1
公开(公告)日:2010-05-13
申请号:US12614584
申请日:2009-11-09
申请人: Hsing-Pang Hsieh , Selvaraj Mohane Coumar , Tsu-An Hsu , Wen-Hsing Lin , Yi-Rong Chen , Yu-Sheng Chao
发明人: Hsing-Pang Hsieh , Selvaraj Mohane Coumar , Tsu-An Hsu , Wen-Hsing Lin , Yi-Rong Chen , Yu-Sheng Chao
IPC分类号: A61K31/519 , C07D491/048 , C07D495/14 , A61P35/04
CPC分类号: C07D491/02 , C07D491/04 , C07D495/02 , C07D495/04 , C07D495/12
摘要: Fused bicyclic or tricyclic compounds of formula (I): wherein A, B, C, X, Y, m, and n are defined herein. Also disclosed are a method for inhibiting EGFR kinase activity and a method for treating cancer with these compounds.
摘要翻译: 式(I)的稠合双环或三环化合物:其中A,B,C,X,Y,m和n如本文所定义。 还公开了抑制EGFR激酶活性的方法和用这些化合物治疗癌症的方法。
-
公开(公告)号:US09006252B2
公开(公告)日:2015-04-14
申请号:US12564218
申请日:2009-09-22
IPC分类号: C07D239/94 , C07D413/12 , C07D403/12 , C07D411/12 , A61K31/4365 , A61K31/517 , A61K31/519 , C07D401/12 , C07D417/12 , C07D417/14 , C12N9/99 , C07D498/04 , C07D215/20 , C07D215/26 , C07D471/04 , C07D495/04 , C07D491/04 , C07D495/14 , C07D513/04 , C07D487/04 , C07D473/34
CPC分类号: A61K31/4365 , A61K31/517 , A61K31/519 , C07D239/94 , C07D401/12 , C07D403/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/04 , C07D495/04 , C07D495/14 , C07D498/04 , C07D513/04 , C12N9/99
摘要: Fused multicyclic compounds of formula (I): wherein R′, R″, X, Y, Z, A, B, C, D, and n are defined herein. Also disclosed are a method for inhibiting protein kinase (e.g., Aurora kinase) activity and a method for treating a protein kinase mediated disorder (e.g., cancer) with these compounds.
摘要翻译: 式(I)的稠合多环化合物:其中R',R“,X,Y,Z,A,B,C,D和n如本文所定义。 还公开了抑制蛋白激酶(例如,极光激酶)活性的方法和用这些化合物治疗蛋白激酶介导的病症(例如癌症)的方法。
-
公开(公告)号:US20100081675A1
公开(公告)日:2010-04-01
申请号:US12564218
申请日:2009-09-22
IPC分类号: A61K31/519 , C07D239/72 , C12N9/99 , A61K31/517 , C07D401/02 , C07D471/02 , A61K31/4365 , A61P35/00
CPC分类号: A61K31/4365 , A61K31/517 , A61K31/519 , C07D239/94 , C07D401/12 , C07D403/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/04 , C07D495/04 , C07D495/14 , C07D498/04 , C07D513/04 , C12N9/99
摘要: Fused multicyclic compounds of formula (I): wherein R′, R″, X, Y, Z, A, B, C, D, and n are defined herein. Also disclosed are a method for inhibiting protein kinase (e.g., Aurora kinase) activity and a method for treating a protein kinase mediated disorder (e.g., cancer) with these compounds.
摘要翻译: 式(I)的稠合多环化合物:其中R',R“,X,Y,Z,A,B,C,D和n如本文所定义。 还公开了抑制蛋白激酶(例如,极光激酶)活性的方法和用这些化合物治疗蛋白激酶介导的病症(例如癌症)的方法。
-
公开(公告)号:US20090149545A1
公开(公告)日:2009-06-11
申请号:US10856281
申请日:2004-05-28
申请人: Tsu-An Hsu , Hsing-Pang Hsieh , Yu-Sheng Chao , Chi-Min Chen , Jia-Tsrong Jan , Hwan-Wun Liu
发明人: Tsu-An Hsu , Hsing-Pang Hsieh , Yu-Sheng Chao , Chi-Min Chen , Jia-Tsrong Jan , Hwan-Wun Liu
IPC分类号: A61K31/166 , A61P31/12
CPC分类号: A61K31/33
摘要: A method for treating coronavirus infection by administering to a subject in need of the treatment an effective amount of one or more of the following compounds: aklavin, sanguinarine, amiodarone, chlorpromazine, clomiphene, dihydroergotamine, dipyridamole, emetine, ephedrine, prochlorperazine, promazine, propiomazine, aminacrine, fluphenazine, fenoterol, peruvoside, proglumide, atenolol, nerifolin, nefopam, cycloheximide, avermectin B1, bepridil, cinnarizine, ethisterone, pararosaniline, methylbenzethonium, niclosamide, pipobroman, homidium, calcimycin, anisomycin, metergoline, amodiaquine, danazol, danthron, ethopropazine, eucatropine, nortriptyline, resorcinol, mebhydrolin, mebeverine, trimipramine, triflupromazine, chlorprothixene, cyclobenzaprine, enoxacin, sulfanitran, monensin, nigericin, perphenazine, methoxamine, astemizole, trifluoperazine, acriflavinium, rotenone, acebutolol, quabain, methiothepin, convallatoxin, halcinonide, cyclosporin, pimethixene, mycophenolic acid, promethazine, mesoridazine, thioridazine, chlorprothixene, thiothixene, clozapine, haloperidol, haloperidol decanoate, loxapine, molindone, olanzapine, pimozide, quetiapine, risperidone, and amitriptyline.
摘要翻译: 一种通过向需要治疗的受试者施用有效量的一种或多种以下化合物来治疗冠状病毒感染的方法:阿伐黄素,血根碱,胺碘酮,氯丙嗪,克罗米酚,二氢麦角胺,双嘧达莫,埃米汀,麻黄素,丙氯拉嗪, 丙诺霉素,氨基吖啶,氟奋乃静,非诺替尔,紫苏碱,恩替洛尔,阿替洛尔,奈非泮,奈非泮,放线菌酮,阿维菌素B1,苯普利,桂酸,乙胺,对羟基苯胺,甲基苄索铵,氯硝柳胺,pipobroman,homidium,calcimycin,茴香霉素,metergoline,amodiaquine,达那唑, 依托泊汀,间苯二酚,替康罗林,美勃司宁,间苯丙胺,三氟丙嗪,氯替噻吩,环苯扎林,依诺沙星,磺胺三苯胺,莫能菌素,尼日利亚,奋乃静,甲氧胺,阿司咪唑,三氟拉嗪,吖啶鎓,鱼藤酮, ,环孢菌素,哌甲酯,霉酚酸, 乙氮嗪,美索达嗪,硫利达嗪,氯普ix辛,硫代四氢噻吩,氯氮平,氟哌啶醇,氟哌啶醇癸酸酯,洛沙平,莫洛多内,奥氮平,匹莫齐特,喹硫平,利培酮和阿米替林。
-
公开(公告)号:US20090111876A1
公开(公告)日:2009-04-30
申请号:US12252662
申请日:2008-10-16
申请人: Hsing-Pang Hsieh , Tsu-An Hsu , Yu-Sheng Chao , Yu-Cheng Chou , Shun Te Wang
发明人: Hsing-Pang Hsieh , Tsu-An Hsu , Yu-Sheng Chao , Yu-Cheng Chou , Shun Te Wang
CPC分类号: A61K36/05
摘要: This invention relates to an extract of Chlorella sorokiniana, which contains myristic acid, palmitic acid, palmitoleic acid, oleic acid, linoleic acid, linolenic acid, and stearic acid. Also related is use of this extract to treat diabetes, obesity, and dyslipidaemia.
摘要翻译: 本发明涉及一种含有肉豆蔻酸,棕榈酸,棕榈油酸,油酸,亚油酸,亚麻酸,硬脂酸的小球藻的提取物。 还涉及使用该提取物治疗糖尿病,肥胖和血脂异常。
-
公开(公告)号:US08710079B2
公开(公告)日:2014-04-29
申请号:US13091895
申请日:2011-04-21
申请人: Hsing-Pang Hsieh , Tsu-An Hsu , Jiann-Yih Yeh , Yu-Sheng Chao
发明人: Hsing-Pang Hsieh , Tsu-An Hsu , Jiann-Yih Yeh , Yu-Sheng Chao
IPC分类号: C07D215/38 , A61K31/04
CPC分类号: C07D401/04 , C07D401/14 , C07D403/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要: Quinoline compounds of formula (I): in which A, B, D, E, F, G, R1, R2, R3, X, Y, n, p, and q are defined herein. Also disclosed is a method for treating a viral infection with a compound of formula (I).
摘要翻译: 式(I)的喹啉化合物:其中A,B,D,E,F,G,R 1,R 2,R 3,X,Y,n,p和q如本文所定义。 还公开了用式(I)化合物治疗病毒感染的方法。
-
公开(公告)号:US07544712B1
公开(公告)日:2009-06-09
申请号:US10856281
申请日:2004-05-28
申请人: Tsu-An Hsu , Hsing-Pang Hsieh , Yu-Sheng Chao , Chi-Min Chen , Jia-Tsrong Jan , Hwan-Wun Liu
发明人: Tsu-An Hsu , Hsing-Pang Hsieh , Yu-Sheng Chao , Chi-Min Chen , Jia-Tsrong Jan , Hwan-Wun Liu
CPC分类号: A61K31/33
摘要: A method for treating coronavirus infection by administering to a subject in need of the treatment an effective amount of one or more of the following compounds: aklavin, sanguinarine, amiodarone, chlorpromazine, clomiphene, dihydroergotamine, dipyridamole, emetine, ephedrine, prochlorperazine, promazine, propiomazine, aminacrine, fluphenazine, fenoterol, peruvoside, proglumide, atenolol, nerifolin, nefopam, cycloheximide, avermectin B1, bepridil, cinnarizine, ethisterone, pararosaniline, methylbenzethonium, niclosamide, pipobroman, homidium, calcimycin, anisomycin, metergoline, amodiaquine, danazol, danthron, ethopropazine, eucatropine, nortriptyline, resorcinol, mebhydrolin, mebeverine, trimipramine, triflupromazine, chlorprothixene, cyclobenzaprine, enoxacin, sulfanitran, monensin, nigericin, perphenazine, methoxamine, astemizole, trifluoperazine, acriflavinium, rotenone, acebutolol, quabain, methiothepin, convallatoxin, halcinonide, cyclosporin, pimethixene, mycophenolic acid, promethazine, mesoridazine, thioridazine, chlorprothixene, thiothixene, clozapine, haloperidol, haloperidol decanoate, loxapine, molindone, olanzapine, pimozide, quetiapine, risperidone, and amitriptyline.
摘要翻译: 一种通过向需要治疗的受试者施用有效量的一种或多种以下化合物来治疗冠状病毒感染的方法:阿伐黄素,血根碱,胺碘酮,氯丙嗪,克罗米酚,二氢麦角胺,双嘧达莫,埃米汀,麻黄素,丙氯拉嗪, 丙诺霉素,氨基吖啶,氟奋乃静,非诺替尔,紫苏碱,恩替洛尔,阿替洛尔,奈非泮,奈非泮,放线菌酮,阿维菌素B1,苯普利,桂酸,乙胺,对羟基苯胺,甲基苄索铵,氯硝柳胺,pipobroman,homidium,calcimycin,茴香霉素,metergoline,amodiaquine,达那唑, 依托泊汀,间苯二酚,替康罗林,美勃司宁,间苯丙胺,三氟丙嗪,氯替噻吩,环苯扎林,依诺沙星,磺胺三苯胺,莫能菌素,尼日利亚,奋乃静,甲氧胺,阿司咪唑,三氟拉嗪,吖啶鎓,鱼藤酮, ,环孢菌素,哌甲酯,霉酚酸, 乙氮嗪,美索达嗪,硫利达嗪,氯普ix辛,硫代四氢噻吩,氯氮平,氟哌啶醇,氟哌啶醇癸酸酯,洛沙平,莫洛多内,奥氮平,匹莫齐特,喹硫平,利培酮和阿米替林。
-
-
-
-
-
-
-
-
-